Brief: Grand Pharmaceutical Says Ryaltris Compound Nasal Spray Granted Drug Registration Certificate By NMPA
10/11/2025 10:22
Nov 10 (Reuters) - Grand Pharmaceutical Group Ltd 0512.HK: RYALTRIS COMPOUND NASAL SPRAY DEVELOPED BY GLENMARK SPECIALTY S.A. GRANTED DRUG REGISTRATION CERTIFICATE BY NMPA Further company coverage: 0512.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement